DBV Technologies S.A. (DBVT)

Market Cap	289.51M
Revenue (ttm)	3.50M
Net Income (ttm)	-113.65M
Shares Out	136.72M
EPS (ttm)	-1.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,062
Open	10.90
Previous Close	10.30
Day's Range	10.55 - 11.99
52-Week Range	2.21 - 12.78
Beta	0.32
Analysts	Buy
Price Target	14.81 (+27.67%)
Earnings Date	Jul 29, 2025

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: DBVT
• Website: https://www.dbv-technologies.com

Financial Performance

In 2024, DBV Technologies's revenue was $4.15 million, a decrease of -73.61% compared to the previous year's $15.73 million. Losses were -$113.92 million, 56.6% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price target is $14.81, which is an increase of 27.67% from the latest price.

Price Target

$14.81

(27.67% upside)

Analyst Consensus: Buy